Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SYHX2011 in Combination With Carboplatin and Enlonstobart Versus Nab-Paclitaxel Plus Carboplatin and Tislelizumab as First-Line Therapy for Squamous Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Phase II/III Study

NCT07662811 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT07662811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07662811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SYHX2011 in Combination With Carboplatin and Enlonstobart Versus Nab-Paclitaxel Plus Carboplatin and Tislelizumab as First-Line Therapy for Squamous Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Phase II/III Study
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
December 31, 2029
Enrollment
396 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer